Int J Clin Pharmacol Ther. 2021 Jun;59(6):467-470. doi: 10.5414/CP203808.
Imatinib, a tyrosine kinase inhibitor, is frequently used to treat unresectable or metastatic gastrointestinal stromal tumors. The application of this medication is considered an adjuvant treatment of gastrointestinal stromal tumors. It can reduce the postoperative recurrence of the tumors. During the treatment with imatinib, there can be various gastrointestinal adverse reactions, which are mild and can be alleviated following a reduction in the dose. It is rare that perforation of the digestive tract happens after the employment of this medication. This study reported that imatinib mesylate caused bowel perforation in one patient with gastric stromal tumors after its use for 3 months.
伊马替尼是一种酪氨酸激酶抑制剂，常用于治疗不可切除或转移性胃肠道间质瘤。该药物的应用被认为是胃肠道间质瘤的辅助治疗方法，可降低肿瘤的术后复发率。在使用伊马替尼的过程中，可能会出现各种胃肠道不良反应，这些反应较为轻微，且在降低剂量后可以得到缓解。但很少会在使用该药物后发生消化道穿孔。本研究报道了 1 例胃间质瘤患者在使用甲磺酸伊马替尼 3 个月后发生肠穿孔。
